News
TEVA
12.99
-0.19%
-0.03
The Sound Shore Fund Q1 2024 Letter To Shareholders
The Sound Shore Fund Investor Class and Institutional Class advanced 17.05% and 17.10% in the first quarter of 2024. The Fund's strong first quarter 2024 gain was substantially ahead of both the Russell Value and S&P 500 indices. The fund's portfolio return was driven by 12 holdings from seven different sectors.
Seeking Alpha · 1d ago
Supreme Court Denies Vanda Pharma' Petition In HETLIOZ Litigation Against Teva, Apotex
NASDAQ · 2d ago
US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
The U.S. Supreme Court has reportedly declined to review Vanda Pharmaceuticals Inc’s attempt to revive patents for its sleep-disorder medication Hetlioz. Vanda had previously had its patents invalidated in a legal battle with generic drugmakers Teva Pharmaceutical Industries.
Benzinga · 3d ago
BUZZ-Vanda Pharma falls as Supreme Court rejects case over sleep-drug patents
U.S. Supreme Court declines to hear bid by Vanda to revive patents for its sleep-disorder drug Hetlioz. Shares of drugmaker Vanda Pharmaceuticals down 6.1% to $4.80. Patents were previously declared invalid in dispute with generic drugmakers Teva.
Reuters · 3d ago
'The U.S Supreme Court Has Reportedly Declined To Hear Vanda Pharmaceuticals' Case Regarding The Invalidation Of Certain Patents For Its Sleep-Wake Disorder Drug Hetlioz, That Were Previously Declared Invalid In A Dispute With Generic Drugmakers Teva And Apotex' - Yahoo Finance
U.S. Supreme Court declines to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz. The company's patents were declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling.
Benzinga · 3d ago
UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents. Vanda wanted to revive patents for its drug Hetlioz that were declared invalid in a dispute with generic drugmakers Teva and Apotex. The justices turned away Vanda's appeal of a ruling against the company.
Reuters · 3d ago
US Supreme Court reportedly declines to hear Vanda patent case
US Supreme Court reportedly declines to hear Vanda Pharmaceuticals' patent case. Vanda had appealed to the high court after a lower court ruled in 2022 that the company's patents for its sleep-wake disorder drug Hetlioz were invalid. The FDA declined to approve a label expansion for the drug last month.
Seeking Alpha · 3d ago
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a favorite amongst institutional investors who own 65%
Institutional investors own 65% of Teva Pharmaceutical Industries Limited (NYSE:TEVA) The top 25 shareholders of the company own 49% of the stock. The company has a history of growing revenue but not as much as other companies. The majority of shares are held by institutions, with the general public owning 34% of company. Teva pharmaceutical Industries has a high level of insider ownership, but the company is not considered to be a reliable indicator of future performance. It's worth looking at the company's ownership of shareholders to get an idea of its future.
Simply Wall St · 3d ago
Weekly Report: what happened at TEVA last week (0415-0419)?
Weekly Report · 3d ago
Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth
Pfizer's share price has fallen about 10% since my last article on the company. The company's sales of respiratory virus vaccine Abrysvo increased 37.3% in the fourth quarter of 2023. I am upgrading Pfizer's rating from 'Buy' to 'Strong Buy' Pfizer is one of the largest pharmaceutical companies.
Seeking Alpha · 6d ago
Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S.
Seeking Alpha · 6d ago
Alvotech Inks Long-Term Agreement With A Strategic Partner To Further Enhance Access To Adalimumab-ryvk In US Market
Teva will continue to commercialize adalimumab-ryvk under the SIMLANDI brand in the U.S. The current multi-product commercialization partnership between Teva Pharmaceuticals and Alvotech remains unchanged.  Alvotech's new partnership agreement supports Teva's financial guidance.
Benzinga · 6d ago
ALVOTECH SA - LONG-TERM AGREEMENT WITH A STRATEGIC PARTNER TO FURTHER ENHANCE ACCESS TO ADALIMUMAB-RYVK IN U.S. MARKET
Reuters · 6d ago
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
NASDAQ · 6d ago
Teva Pharmaceutical Revamps Financial Reporting Structure
TipRanks · 04/18 20:23
Teva Pharmaceuticals Decided That Canada Will No Longer Be Included As Part Of Teva's North America Segment As Of Jan. 1, 2024
Benzinga · 04/18 20:09
TEVA: CANADA WILL BE REPORTED AS PART OF TEVA'S INTERNATIONAL MARKETS SEGMENT
Reuters · 04/18 20:07
TEVA: DECIDED THAT CANADA WILL NO LONGER BE INCLUDED AS PART OF TEVA'S NORTH AMERICA SEGMENT AS OF JANUARY 1, 2024
Reuters · 04/18 20:07
CVS favors Humira copycats hurting AbbVie’s market share: Evercore
Seeking Alpha · 04/17 13:26
FDA approves Alvotech biosimilar of J&J top-selling drug Stelara
Seeking Alpha · 04/16 22:22
More
Webull provides a variety of real-time TEVA stock news. You can receive the latest news about Teva Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.